Skip to main content
Premium Trial:

Request an Annual Quote

Guardant Health to Acquire Bellwether Bio

NEW YORK (GenomeWeb) - Guardant Health said today that it has entered a definitive agreement to acquire Bellwether Bio, a privately held firm formed two years ago to advance a method for early blood-based cancer detection that relies on detecting epigenetic signals in circulating cell free DNA.

Under the agreement, the Bellwether Bio team, which includes University of Washington professor Jay Shendure, will join the effort to advance Guardant’s own early detection product pipeline dubbed LUNAR. Guardant said Shendure will act as a scientific advisor.

Financial terms of the deal, expected to close in April, were not disclosed.

Seattle-based Bellwether was formed to commercialize research on nucleosome positioning and fragmentomics, which was described in Cell in 2016 by investigators at UW.

"We are excited to welcome the Bellwether team and believe they will enhance our product pipeline as we seek to expand precision oncology to earlier stages of disease," Guardant Health President and Co-founder AmirAli Talasaz said in a statement. "Our early research has shown the strong potential impact of incorporating biologically relevant epigenomic information on the clinical performance of blood tests for early-stage cancer detection."

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.